Latozinemab
Product Specifications
UNSPSC Description
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2].
Target Antigen
Neurotensin Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein;Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/latozinemab.html
Purity
95.00
Solubility
H2O
Smiles
[Latozinemab]
References & Citations
[1]Sam Jackson, et al. Six months interim analysis of the phase 2 study of AL001 in frontotemporal dementia patients carrying a granulin mutation. Alzheimer's & DementiaVolume 17: Drug Development.|[2]Robert Paul, et al. AL001 Blocks the Sortilin/PGRN Interaction and is a Potential Therapy for FTD-GRN (4422). Neurology, April 13, 2021; 96 (15 Supplement).
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99688/Latozinemab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99688/Latozinemab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
